U.S. flag

An official website of the Department of Health & Human Services

AHRQ: Agency for Healthcare Research and Quality

Substance Use Tools & Resources   

Read the Guide

This collection of tools and resources is for providers, staff, and patients who offer or use services to address substance use, and other interested stakeholders. This collection was originally established following an environmental scan on implementing medication-assisted treatment (MAT) for opioid use disorder (OUD) in rural primary care. (See PDFs of Volume 1 [PDF 0.69 MB] and Volume 2 [PDF 1.28 MB] of that scan). Items have been continuously added to this collection since then, and the collection has expanded to cover substance use more broadly, rather than just MAT for OUD.

Displaying 21 - 30 of 120

CDC Opioid Guideline Mobile App

Helps providers apply recommendations to clinical practice by putting the entire guideline, tools, and resources in an app. Includes a morphine milligram equivalent calculator, summaries of key recommendations, a link to the full guideline, and an interactive motivational interviewing feature to help providers practice effective communication skills and prescribe with confidence.

Format
Guide
Audience
Medical Providers
Source
Centers for Disease Control and Prevention
Year

Evaluation of Mental Health Mobile Applications

This Technical Brief proposes a framework to assess mental health mobile applications, including those related to substance use, with the aim to facilitate selection of apps. The results of applying the framework will yield summary statements on the strengths and limitations of the apps and are intended for use by providers and patients/caregivers.
Format
Report/Paper/Issue Brief
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
Agency of Healthcare Research and Quality (AHRQ)
Year
Resource Type
PDF
File Size
8.1 MB

Fentanyl Drug Checking and Screening: Roundtable on Clinical Perspectives Summary Report

This document summarizes the discussion from the meeting of clinicians and researchers who are knowledgeable about screening for fentanyl and other drugs, primarily in health care settings. The focus of the meeting was to understand clinician/researcher perspectives about clinical fentanyl testing and distribution of fentanyl test strips (FTS) to patients and discuss next steps for technology development, research, and practice.
Format
Report/Paper/Issue Brief
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
Reagan-Udall Foundation for the FDA (Food and Drug Administration)
Year
Resource Type
PDF
File Size
562 KB

Fentanyl Drug Checking and Screening: Roundtable on Community Perspectives Summary Report

These proceedings summarize the discussion from the harm reduction community roundtable and supplemental individual interviews, inclusive of representatives from national and local harm reduction organizations, state and local government agencies, tribal organizations, and researchers who have experience distributing fentanyl test strips (FTS) or are knowledgeable about FTS specifically or drug checking more generally.

Format
Report/Paper/Issue Brief
Audience
Behavioral Health Providers
Communities
Medical Providers
Other Team Members
Source
Reagan-Udall Foundation for the FDA (Food and Drug Administration)
Year
Resource Type
PDF
File Size
593 KB

Food and Drug Administration Overdose Prevention Framework

The FDA Overdose Prevention Framework consists of four overarching priorities that align with the U.S. Department of Health & Human Services' Overdose Prevention Strategy to address the public health emergency as it continues to evolve.
Format
Toolkit
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
Food and Drug Administration (FDA)
Year
Resource Type
PDF
File Size
146 KB

Index to Drug-Specific Information

This FDA page provides an index of over 400 FDA approved drugs and their descriptions. Note that it does not include all FDA approved drugs, but shares other resources to find more information on drugs not included on the list.

Format
Web Page
Audience
Behavioral Health Providers
Medical Providers
Source
U.S. Food and Drug Administration (FDA)
Year
Resource Type
Web Page

Margolis-FDA Workshop: Identifying Key Competencies for Opioid Prescriber Education

This was a two-day virtual public workshop (which can now be re-watched) that focused on identifying gaps in existing opioid prescriber education offerings and core competencies that should be included in educational content for opioid prescribers and other healthcare providers, including prescriber education under a Risk Evaluation and Mitigation Strategy (REMS).
Format
Webinar/Video
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Policymakers and Payers
Source
Duke-Margolis Center for Health Policy / Food and Drug Administration (FDA)
Year
Resource Type
Video

Medication for Opioid Use Disorder (MOUD) Tool Kit for Peer Recovery Specialists

This toolkit is a resource for Peer Recovery Specialists (PRSs) to feel equipped to discuss MOUD with providers, people seeking recovery, and others with questions about this treatment option.
Format
Toolkit
Audience
Other Team Members
Source
Association for Multidisciplinary Education and Research in Substance Use and Addiction (AMERSA)
Year
Resource Type
PDF
File Size
3.6 MB

NIH HEAL Initiative

The Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, is an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis.
Format
Campaign
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Policymakers and Payers
Source
National Institutes of Health (NIH)
Year
Resource Type
Web Page

The FDA SOURCE Model

The primary objectives of the SOURCE (Simulation of Opioid Use, Response, Consequences, and Effects) model are threefold: help the FDA and other stakeholders identify high-impact opioid-related interventions, assess potential unanticipated consequences of potential policies, and identify needs for further research.
Format
Instrument/Protocol
Audience
States
Policymakers and Payers
Source
Food and Drug Administration (FDA)
Year
Resource Type
Web Page